Zhengyang Guo

Zhengyang Guo

Auto-generated profile, based on publicly available information

Zhengyang Guo

Center of Basic Medical Research Institute of Medical Innovation and Research Peking University Third Hospital Beijing China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in EBioMedicine
Verified
Journal Article
Open access
ZGZhengyang Guo
Zhengyang Guo
YWYuqing Wang
Yuqing Wang
JSJiagui Song
Jiagui Song
YSYing Song
Ying Song
YBYang Bai
Yang Bai
LXLixiang Xue
Lixiang Xue
Ovarian cancer (OC) is the most aggressive and lethal gynaecological cancer and is characterised by abnormal lipid metabolism. Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It functions as a tumour promoter through both canonical H3K27me3 modification and noncanonical mechanisms. Although EZH2 has been developed as a potential anticancer target, the therapeutic effects of EZH2 inhibitors in solid tumours are still limited. The levels of fatty acid and tricarboxylic acid (TCA) cycle-related metabolites were measured via high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). EZH2-knockout cells, ChIP‒qPCR, qPCR, and western blotting were used to investigate the regulatory effect of EZH2 on FADS2. The expression of FADS2 transcript variants and their correlations with prognosis in clinical OC tissues were analysed via the GEPIA 2 database. Various OC cell lines, patient-derived organoids and tumour-bearing models have been used to test the therapeutic effects of EZH2 and FADS2 inhibitors. 4D-DIA proteomics, the Seahorse assay and flow cytometry-based detection of mitochondrial function and protein synthesis were performed to explore the mechanism of combined therapy. EZH2 knockout increased FADS2 variant 1 (v1) and decreased variant 2/3 (v2/3) at both the mRNA and protein levels. EZH2 occupied the promoters of FADS2 v1 and v2/3, but the enrichment of H3K27me3 at the v2/v3 promoter was significantly lower than that at the v1 promoter. Furthermore, EZH2 inhibitors increased full-length FADS2 v1 expression and polyunsaturated fatty acid abundance in OC cells. A high FADS2 v1/v2 ratio was associated with poor prognosis in patients with OC. Targeting FADS2 with shRNAs or inhibitors reduced EZH2 levels and sensitised cancer cells to EZH2 inhibitors. The combined inhibition of EZH2 and FADS2 induced mitochondrial dysfunction and energy stress and synergised to reduce tumour growth in vitro and in vivo. EZH2 inhibition increases the proportion of the full FADS2 isoform through differential regulation, which suggests a poor prognosis in OC patients. Simultaneous inhibition of EZH2 and FADS2 causes mitochondrial dysfunction and energy stress in OC, resulting in a more pronounced antitumour effect. Our study reveals a mechanistic connection between EZH2 and FADS2 and provides a potential therapeutic strategy for OC. This work was supported by the Youth Program of the National Natural Science Foundation of China (No. 82203102, No. 82303801, No. 82203433), the National Key Research and Development Program of China (2022YFA1104001), the General Program of the National Natural Science Foundation of China (No. 82272745, No. 82072870, No. 81972966, No. 82373173, No. 82073057), and the Peking University Third Hospital Clinical Key Project (BYSY2022069, BYSY2022070, BYSYZD2023010).

14 November 2025 in Research Square
Verified
Preprint
Open access
PDF file
LXLixiang Xue
Lixiang Xue
JSJiagui Song
Jiagui Song
XHXiao Huo
Xiao Huo
YGYunyun Guo
Yunyun Guo
THTianhui He
Tianhui He
ZGZhengyang Guo
Zhengyang Guo
Current histopathological classification systems for ovarian cancer cannot adequately predict platinum chemotherapy response, hindering personalized therapeutic strategies. Here, through integrative analysis of multiple datasets from TCGA, ICGC and GEO databases, we stratify patients into metabolic associated chemotherapy-refractory and chemotherapy-sensitive types (MCRT, MCST for short) with distinct prognosis by 20 genes. Lipidomic profiling of ascites from patients with ovarian cancer further identifies oleic acid as a hallmark metabolite in MCRT cases. Oleic acid treatment facilitates the resistance to cisplatin in ovarian cancer cells and patient-derived organoids. Mechanistically, oleic acid activates and promotes nuclear translocation of YAP through CD36. Inhibition of SCD1—genetically or pharmacologically—synergizes with cisplatin in 26 patient-derived organoids and suppresses tumor growth in xenograft models. Our study proposes a new metabolic classification of ovarian cancer that can predict chemotherapy sensitivity. Moreover, it discovers the role of the oleic acid-CD36-YAP signaling axis in promoting cisplatin resistance. These findings shed light on how oleic acid facilitates the resistance to cisplatin in ovarian cancer and provide a potential therapeutic strategy for treating patients with ovarian cancer.

2 November 2026 in Clinical and Translational Medicine
Verified
Journal Article
Open access
JSJiagui Song
Jiagui Song
ZGZhengyang Guo
Zhengyang Guo
DYDecao Yang
Decao Yang
PYPing Yu
Ping Yu
YLYinjia Li
Yinjia Li
TLTong Liu
Tong Liu
Background: Ovarian cancer (OC) remains the most lethal gynaecological malignancy, and acquired resistance to PARP inhibitors such as olaparib represents a major clinical challenge. Although dysregulation of iron metabolism has been implicated in tumorigenesis, the specific role of the iron exporter SLC40A1 (ferroportin, FPN) in mediating olaparib resistance remains poorly understood. The study aimed to elucidate the clinical significance of FPN deficiency and to explore therapeutic strategies for reversing olaparib resistance. Methods: FPN expression was evaluated in OC samples from a clinical cohort of 19 patients, stratified by olaparib responsiveness, to determine its prognostic value. Functional mechanisms were investigated using multiple OC cell lines, patient‐derived organoids (PDOs), and mouse xenograft models. We integrated analyses of iron homeostasis, ROS dynamics, DNA repair capacity, and innate immune signaling, with a focus on the cGAS–STING–STAT3 signaling cascade. The therapeutic potential of combining olaparib with the ferroptosis inducer erastin or the STING inhibitor C‐176 was assessed as a strategy to overcome FPN deficiency‐driven resistance. Results: Clinically, FPN expression was significantly downregulated in olaparib‐resistant tissues compared with sensitive controls ( p < 0.05), and low FPN levels were strongly associated with poor therapeutic outcomes. Mechanistically, FPN deficiency promoted intracellular iron accumulation and ROS generation, which led to increased ferroptosis vulnerability, impaired homologous recombination repair (HRR) and concomitant activation of the cGAS–STING–STAT3 inflammatory axis, thereby driving olaparib resistance. Notably, in vivo studies demonstrated that combining olaparib with either erastin or C‐176 significantly suppressed tumour growth and restored drug sensitivity compared with monotherapy ( p < 0.01), supporting the translational potential of targeting this axis. Conclusions: Our study establishes a clinically relevant mechanistic connection between ferroportin deficiency and cGAS–STING–STAT3‐mediated olaparib resistance in OC. We identify the FPN–ROS–cGAS–STING–STAT3 axis as an actionable vulnerability in resistant OC, indicating that this pathway is a promising therapeutic target to overcome olaparib resistance. Highlights: FPN loss drives olaparib resistance and predicts poor outcomes in ovarian cancer. FPN loss causes iron and ROS accumulation, impairing HRR and activating the cGAS–STING–STAT3 axis. The cGAS–STING–STAT3 pro‐survival program drives olaparib resistance. STING inhibition restores olaparib sensitivity in resistant ovarian cancer.

5 November 2026 in Cell Reports
Verified
Journal Article
Open access
YTYuanjun Tang
Yuanjun Tang
ZHZhanya Huang
Zhanya Huang
YJYiting Jia
Yiting Jia
YGYunyun Guo
Yunyun Guo
XCXuedi Cao
Xuedi Cao
LXLixiang Xue
Lixiang Xue